The Phase 3 trial will assess the efficacy of PBI-4050 both as a stand-alone treatment and as an add-on to Ofev, and will integrate a dataset supporting a simple, all-inclusive indication for IPF treatment. The multi-center study will be conducted at sites across the U.S., Canada, Australia, the U.K., and Europe. Prometic anticipates starting patient enrollment in mid-2018.

“Idiopathic pulmonary fibrosis (IPF) is now priority No.1 for PBI-4050” Pierre Laurin, president and CEO of Prometic, said in a press release.

“IPF remains to this day a significant unmet medical need affecting hundreds of thousands of patients … The clinical efficacy demonstrated so far in multiple phase 2 clinical trials combined with an impressive safety and tolerability profile gives us great confidence in PBI-4050’s ability to efficiently address fibrotic diseases,” Laurin added.

A Phase 2 study (NCT02538536) in 40 IPF patients reported a stabilization in lung function among those given PBI-4050 as a stand-alone therapy or in combination with Ofev after 12 weeks of treatment, while a significant further decline was seen in those taking PBI-4050 plus Esbriet.

As part of its clinical realignment, Prometic terminated clinical trials of PBI-4050 in cystic fibrosis-related diabetes and is evaluating other programs underway. The company is also analyzing the development of PBI-4050 analogs (similar compounds), which demonstrated similar effects or even outperformed PBI-4050 in preclinical studies. These analogs could enable targeting other fibrotic-related indications, the company said.

Prometic also hopes to bring Ryplazim (plasminogen) to the market to treat as a treatment of congenital plasminogen deficiency. It is awaiting the review of its Biologic License Application submitted to the U.S. Food and Drug Administration (FDA).

Patients with IPF may also benefit from Ryplazim, Prometic states. The body converts plasminogen to the enzyme plasmin, which is key in wound healing and could work to reduce IPF flares. The company plans to test Ryplazim in IPF patients in upcoming clinical trials. The treatment candidate recently received orphan drug status by the FDA, a designation for medications that intend to treat disorders affecting fewer than 200,000 patients in the U.S

In addition, Prometic is developing PBI-4050 as a treatment for Alström syndrome, a rare, genetic, multi-organ disease. Current data from prolonged treatment with PBI-4050 in a Phase 2 trial (NCT02739217) in the U.K. supports the treatment candidate’s use as a stand-alone medication in this patient population. The company plans to meet with regulatory agencies in the U.S. and Europe regarding this program.

“Safety and efficacy data collected and demonstrated to date in such a challenging patient population will also contribute to the clinical design and potential treatment for future clinical development initiatives of the Corporation with respect to indications such as heart, kidney & liver fibrosis,” Laurin said.

I am on OFEV, the side effects are not pleasant, however, I am still breathing with difficulties.
I still maintain that this disease is work related. Worked in the metal industry for over 40 years, welding, grinding and lots of small molecules (polluted air) around at all times while at work.

i am 76 years old and was diagnosed in 2009 with interstitial pneumonitis. apart from an initial cocktail of drugs which didn’t help i have received no further treatment until 2016, by which time i was on oxygen therapy, 2ltrs at rest and 6 ltrs walking, when i was offered a trial place for nantidinab. half way through I fell down the stairs and broke all three bones in my ankle, and was laid up for a few months and the trial was suspended. In july 2017 I started back on the drug trial but suffered a mild heart attack and had to come off it. during the period of being laid up my breathing deteriorated and I am now on 3.5 ltrs at rest and 15 ltrs for walking. I am told that my lung function is not bad enough to warrant any treatment on the nhs. I have read that early diagnosis is vital but I don’t understand why.

Pulmonary Fibrosis News

Disclaimer:

Pulmonary Fibrosis News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Pin It on Pinterest

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. We never use your cookies for creepy ad retargeting that follows you around the web. OkRead more